<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A 14-year-old adolescent was seen with an 8-month history of almost daily incapacitating <z:hpo ids='HP_0002315'>headaches</z:hpo> due to idiopathic intracranial <z:hpo ids='HP_0000822'>hypertension</z:hpo> in <z:chebi fb="6" ids="22696">Beh</z:chebi>Ã§et syndrome </plain></SENT>
<SENT sid="1" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> his clinical signs and symptoms, including <z:hpo ids='HP_0002315'>headache</z:hpo>, resolved 2 to 4 weeks after topiramate was initiated </plain></SENT>
<SENT sid="2" pm="."><plain>An effect on carbonic anhydrase isoenzymes II and IV, reducing cerebrospinal fluid production, could potentially explain the beneficial effect of topiramate in intracranial <z:hpo ids='HP_0000822'>hypertension</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Further studies are necessary, however, to confirm the significance of topiramate in this indication </plain></SENT>
</text></document>